Profile data is unavailable for this security.
About the company
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
- Revenue in USD (TTM)28.01m
- Net income in USD-50.90m
- Incorporated2014
- Employees65.00
- LocationZevra Therapeutics Inc1180 CELEBRATION BOULEVARD, SUITE 103CELEBRATION 34747United StatesUSA
- Phone+1 (321) 939-3416
- Fax+1 (319) 665-2577
- Websitehttps://zevra.com/
Mergers & acquisitions
Acquired company | ZVRA:NSQ since announced | Transaction value |
---|---|---|
Acer Therapeutics Inc | -12.08% | 91.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Achieve Life Sciences Inc | 0.00 | -27.32m | 185.79m | 22.00 | -- | 3.75 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
P3 Health Partners Inc | 1.35bn | -67.27m | 186.51m | 400.00 | -- | 0.4806 | -- | 0.1379 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Galectin Therapeutics Inc | 0.00 | -44.78m | 189.55m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
Capricor Therapeutics Inc | 27.10m | -24.31m | 190.55m | 101.00 | -- | 10.27 | -- | 7.03 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Puma Biotechnology Inc | 226.63m | 15.38m | 192.96m | 185.00 | 12.43 | 3.78 | 7.17 | 0.8514 | 0.3219 | 0.3219 | 4.74 | 1.06 | 1.10 | 10.95 | 8.13 | 1,225,016.00 | 7.49 | -12.21 | 11.65 | -20.53 | 73.44 | 78.78 | 6.78 | -11.79 | 1.38 | 2.57 | 0.6624 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Omeros Corp | 0.00 | -179.09m | 194.11m | 198.00 | -- | -- | -- | -- | -2.90 | -1.97 | 0.00 | -1.23 | 0.00 | -- | -- | 0.00 | -35.90 | -55.51 | -44.81 | -70.10 | -- | -- | -- | -- | -- | -5.39 | 1.19 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
Zevra Therapeutics Inc | 28.01m | -50.90m | 195.04m | 65.00 | -- | 3.99 | -- | 6.96 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4929 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Lineage Cell Therapeutics Inc | 8.00m | -23.66m | 198.27m | 75.00 | -- | 2.74 | -- | 24.77 | -0.1344 | -0.1344 | 0.0455 | 0.3836 | 0.0722 | -- | 57.16 | 106,706.70 | -21.32 | -19.53 | -24.82 | -22.59 | 91.88 | 89.13 | -295.30 | -370.88 | -- | -- | 0.0018 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 199.57m | 1.00 | -- | 66.16 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
INmune Bio Inc | 131.00k | -34.50m | 200.00m | 11.00 | -- | 6.25 | -- | 1,526.72 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Compass Therapeutics Inc. | 0.00 | -45.44m | 202.26m | 32.00 | -- | 1.29 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
Generation Bio Co | 9.96m | -169.06m | 204.24m | 174.00 | -- | 1.55 | -- | 20.50 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 204.27m | 51.00 | -- | 0.7796 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
Scilex Holding Co | 47.05m | -160.60m | 204.74m | 106.00 | -- | -- | -- | 4.35 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Nantahala Capital Management LLCas of 31 Mar 2024 | 2.45m | 5.65% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.20m | 5.07% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.68m | 3.86% |
Woodline Partners LPas of 31 Mar 2024 | 1.01m | 2.33% |
683 Capital Management LLCas of 31 Mar 2024 | 800.00k | 1.84% |
Geode Capital Management LLCas of 31 Mar 2024 | 787.02k | 1.81% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 683.17k | 1.57% |
Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 660.17k | 1.52% |
The Retirement Planning Co. of New England, Inc.as of 31 Mar 2024 | 430.19k | 0.99% |
Altium Capital Management LPas of 31 Mar 2024 | 341.46k | 0.79% |